Target intelligence / Profile preview

Solute carrier family 12 member 1 (SLC12A1) (NKCC2)

Target
NKCC2
Molecular classification
Transporter, Solute carrier, Cation-chloride cotransporter
01

Overview

Solute carrier family 12 member 1 (SLC12A1), commonly known as NKCC2, is a kidney-specific symporter located on the apical membrane of the thick ascending limb of the loop of Henle [4, 9, 10]. It plays a pivotal role in renal physiology by mediating the electroneutral reabsorption of one sodium, one potassium, and two chloride ions from the tubular lumen into the epithelial cells [9, 14, 15]. This process accounts for approximately 20-25% of the total filtered sodium chloride and is essential for the generation of the medullary osmotic gradient required for urine concentration [14, 15, 19]. NKCC2 also functions as a sensor in the macula densa to regulate the tubuloglomerular feedback mechanism and renin secretion [12, 15]. Clinically, NKCC2 is the primary target of loop diuretics such as furosemide, which compete for the chloride-binding site to inhibit ion transport, thereby promoting diuresis and natriuresis [1, 5, 7]. These drugs are widely used to manage hypertension and edematous states associated with heart failure, cirrhosis, and renal disease [5, 7, 12]. Loss-of-function mutations in the SLC12A1 gene lead to Bartter syndrome type I, a severe salt-wasting disorder characterized by hypokalemia and metabolic alkalosis [4, 13, 16].

Other names
Na-K-2Cl cotransporter 2BSC1Bumetanide-sensitive cotransporter 1Sodium-potassium-chloride symporter
02

Mechanism of action

Inhibition of the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle by competing for the chloride-binding site, which prevents the reabsorption of sodium, potassium, and chloride ions.

03

Biological functions

Renal salt reabsorptionUrine concentrationTubuloglomerular feedbackBlood pressure regulationElectrolyte homeostasis
04

Disease associations

HypertensionEdemaBartter syndrome type ICongestive heart failureChronic kidney disease
05

Safety considerations

HypokalemiaHyponatremiaMetabolic alkalosisOtotoxicityDehydrationHypamagnesemiaHyperuricemia
06

Interacting drugs

Furosemide

3 more in the full profile.

07

Biomarkers

Urinary sodium excretionUrinary potassium excretionUrine volumeBlood pressureSerum potassium levelsPlasma renin activity

Beyond the preview

Go deeper on Solute carrier family 12 member 1 (SLC12A1) (NKCC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 12 member 1 (SLC12A1) (NKCC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call